Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAND567 in Hospitalized COVID-19
NCT06012565Phase 2Terminated
- Sponsor
- Kancera
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rugocrixan in coronavirus disease 2019 (COVID-19), sponsored by Kancera. Started Oct 2020; status: terminated.
02
Drugs
rugocrixan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06012565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012565.